Cited by 1,070Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchVirology and Viral Diseases

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Open access

Cunningham, Anthony L., Lal, Himal, Kovac, Martina, Chlibek, Roman, Hwang, Shinn-Jang, Díez-Domingo, Javier, Godeaux, Olivier, Levin, Myron J., McElhaney, Janet E., Puig-Barberà, Joan, Vanden Abeele, Carline, Vesikari, Timo, Watanabe, Daisuke, Zahaf, Toufik, Ahonen, Anitta, Athan, Eugene, Barba-Gomez, Jose F., Campora, Laura, de Looze, Ferdinandus, Downey, H. Jackson, Ghesquiere, Wayne, Gorfinkel, Iris, Korhonen, Tiina, Leung, Edward, McNeil, Shelly A., Oostvogels, Lidia, Rombo, Lars, Smetana, Jan, Weckx, Lily, Yeo, Wilfred, Heineman, Thomas C.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603800

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603800

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citation
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citation
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 866
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Herpes Zoster
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Postherpetic Neuralgia
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 3

Harpaz R, 2008, MMWR Recomm Rep, 57, 1
Chen N, 2014, Cochrane Database Syst Rev, CD006866
2011, MMWR Morb Mortal Wkly Rep, 60, 1528

Sorted by citations

Items 101–200 of 1,000

Herpes Zoster and Diabetes Mellitus: A Review
Papagianni, M., Metallidis, S., & Τζιόμαλος, Κ. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0394-4 · Cited by 81
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults
Schwarz, T. F., Volpe, S. V., Catteau, G., Chlíbek, R., David, M. P., Richardus, J. H., Lal, H., Oostvogels, L., Pauksens, K., Ravault, S., et al. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1442162 · Cited by 81
Self-citation
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 80
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation
Baumrin, E., Voorhees, A. V., Garg, A., Feldman, S. R., & Merola, J. F. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.03.017 · Cited by 79
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
Schwarz, T. F., Aggarwal, N., Moeckesch, B., Schenkenberger, I., Claeys, C., Douha, M., Godeaux, O., Grupping, K., Heineman, T. C., López‐Fauqued, M., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix481 · Cited by 78
Self-citation
The Spectrum of Neurological Manifestations of Varicella–Zoster Virus Reactivation
Kennedy, P. G. E. (2023) · Viruses · doi:10.3390/v15081663 · Cited by 77
Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates
Monslow, M. A., Elbashir, S., Sullivan, N. L., Thiriot, D. S., Ahl, P., Smith, J., Miller, E., Cook, J., Cosmi, S., Thoryk, E., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.062 · Cited by 75
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans
Burny, W., Marchant, A., Hervé, C., Callegaro, A., Caubet, M., Fissette, L. A., Gheyle, L., Legrand, C., N'Dour, C. T., Silva, F. T. D., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.02.015 · Cited by 74
A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations
Ismail, S. J., Hardy, K., Tunis, M. C., Young, K., Sicard, N., & Quach, C. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.051 · Cited by 81
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
Curran, D., Patterson, B. J., Varghese, L., Oorschot, D. V., Buck, P. O., Carrico, J., Hicks, K. A., Lee, B., & Yawn, B. P. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.005 · Cited by 74
The development of COVID-19 vaccines in the United States: Why and how so fast?
Kuter, B. J., Offit, P. A., & Poland, G. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.077 · Cited by 73
Post-herpetic neuralgia – a review of current management and future directions
Schutzer-Weissmann, J. M., & Farquhar-Smith, P. W. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1392508 · Cited by 73
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
Grupping, K., Cámpora, L., Douha, M., Heineman, T. C., Klein, N. P., Lal, H., Peterson, J., Vastiau, I., & Oostvogels, L. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix482 · Cited by 72
Self-citation
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
Dagnew, A. F., Rausch, D. A., Hervé, C., Zahaf, T., Levin, M. J., Schuind, A., & for the ZOE-50/70 study group (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa424 · Cited by 72
Self-citation
Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis
Xia, Y., Zhang, X., Zhang, L., & Fu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978203 · Cited by 77
Varicella and herpes zoster vaccine development: lessons learned
Warren‐Gash, C., Forbes, H. J., & Breuer, J. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1394843 · Cited by 71
Neurological and Ophthalmological Manifestations of Varicella Zoster Virus
Kedar, S., Jayagopal, L. N., & Berger, J. R. (2018) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000721 · Cited by 70
Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines
Dooling, K. L., Guo, A., Patel, M., Lee, G. M., Moore, K. L., Belongia, E. A., & Harpaz, R. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14683 · Cited by 69
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials
López‐Fauqued, M., Cámpora, L., Delannois, F., Idrissi, M. E., Oostvogels, L., de Looze, F. J., Díez‐Domingo, J., Heineman, T. C., Lal, H., McElhaney, J. E., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.03.043 · Cited by 68
Self-citation
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
Ruckwardt, T. J., Morabito, K. M., Phung, E., Crank, M. C., Costner, P. J. M., Holman, L. A., Chang, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00098-9 · Cited by 68
Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection
Alexander, K. E., Tong, P. L., Macartney, K. K., Beresford, R., Sheppeard, V. K., & Gupta, M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.078 · Cited by 68
A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus
Bharucha, T., Ming, D. K. Y., & Breuer, J. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1317410 · Cited by 67
Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis
Gidengil, C. A., Goetz, M. B., Newberry, S. J., Maglione, M., Hall, O., Larkin, J., Motala, A., & Hempel, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.079 · Cited by 75
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
Francica, J. R., Flynn, B. J., Foulds, K. E., Noe, A. T., Werner, A. P., Moore, I. N., Gagné, M., Johnston, T. S., Tucker, C., Davis, R. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi4547 · Cited by 89
Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood
Laupèze, B., Hervé, C., Pasquale, A. D., & Silva, F. T. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.07.098 · Cited by 71
Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster Vaccine
Parameswaran, G. I., Wattengel, B. A., Chua, H. C., Swiderek, J., Fuchs, T. A., Carter, M. T., Goode, L., Doyle, K. M., & Mergenhagen, K. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac549 · Cited by 65
Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22–23 March 2017
Aguado, M. T., Barratt, J., Beard, J., Blomberg, B. B., Chen, W. H., Hickling, J., Hyde, T. B., Jit, M., Jones, R., Poland, G. A., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.029 · Cited by 65
Topical review on nano-vaccinology: Biochemical promises and key challenges
Zaheer, T., Pal, K., & Zaheer, I. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.09.028 · Cited by 65
A Practical Guide to the Safety and Monitoring of New IBD Therapies
Click, B. H., & Regueiro, M. D. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy313 · Cited by 64
Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
Hesse, E. M., Shimabukuro, T. T., Su, J. R., Hibbs, B. F., Dooling, K. L., Goud, R., Lewis, P., Ng, C. S., & Cano, M. V. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6804a4 · Cited by 63
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations
Prosser, L. A., Harpaz, R., Rose, A. M., Gebremariam, A., Guo, A., Ortega‐Sanchez, I. R., Zhou, F., & Dooling, K. L. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2347 · Cited by 63
Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
Curran, D., Oostvogels, L., Heineman, T. C., Matthews, S., McElhaney, J. E., McNeil, S., Díez‐Domingo, J., Lal, H., Andrews, C. P., Athan, E., et al. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly150 · Cited by 62
Self-citation
Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study
Harris, R. C., Sumner, T., Knight, G. M., Evans, T., Cárdenas, V., Chen, C., & White, R. G. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30452-2 · Cited by 62
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Le, P., & Rothberg, M. B. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.7431 · Cited by 61
Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States
Talbird, S. E., La, E. M., Carrico, J., Poston, S. A., Poirrier, J., DeMartino, J. K., & Hogea, C. S. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1780847 · Cited by 65
Vaccines for older adults
Cunningham, A. L., McIntyre, P. B., Subbarao, K., Booy, R., & Levin, M. J. (2021) · BMJ · doi:10.1136/bmj.n188 · Cited by 64
Self-citation
Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013
Genito, C. J., Beck, Z., Phares, T. W., Kalle, F., Limbach, K. J., Stefaniak, M. E., Patterson, N. B., Bergmann‐Leitner, E. S., Waters, N. C., Matyas, G. R., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.070 · Cited by 59
Vaccination programs for older adults in an era of demographic change
Doherty, M. T., Connolly, M. P., Giudice, G. D., Flamaing, J., Goronzy, J. J., Grubeck‐Loebenstein, B., Lambert, P., Maggi, S., McElhaney, J. E., Nagai, H., et al. (2018) · European Geriatric Medicine · doi:10.1007/s41999-018-0040-8 · Cited by 61
Self-citation
Polyomavirus‐driven Merkel cell carcinoma: Prospects for therapeutic vaccine development
Tabachnick‐Cherny, S., Pulliam, T., Church, C. D., Koelle, D. M., & Nghiem, P. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23190 · Cited by 69
Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System
Perciani, C. T., Liu, L. Y., Wood, L. M., & MacParland, S. A. (2020) · ACS Nano · doi:10.1021/acsnano.0c08913 · Cited by 60
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2018
Kim, D. K., Riley, L. E., & Hunter, P. H. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6705e3 · Cited by 59
How aging impacts vaccine efficacy: known molecular and cellular mechanisms and future directions
Chen, J., Deng, J. C., & Goldstein, D. R. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.09.008 · Cited by 61
Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting
Zerbo, O., Bartlett, J., FIREMAN, B. H., Lewis, N., Goddard, K., Dooling, K. L., Duffy, J., Glanz, J. M., Naleway, A. L., Donahue, J. G., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2023 · Cited by 59
Vaccines for preventing herpes zoster in older adults
Gagliardi, A. M., Andriolo, B. N., Torloni, M. R., Soares, B. G., Gomes, J. D. O., Andriolo, R. B., & Cruz, E. C. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008858.pub4 · Cited by 60
Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention
Litt, J. C. B., Cunningham, A. L., Arnalich‐Montiel, F., & Parikh, R. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00990-7 · Cited by 66
Self-citation
Dermatological Complications After Solid Organ Transplantation
Naldi, L., Venturuzzo, A., & Invernizzi, P. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8657-9 · Cited by 59
Life-course immunization as a gateway to health
Philip, R. K., Attwell, K., Breuer, T., Pasquale, A. D., & Lopalco, P. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1527690 · Cited by 57
The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis
McGirr, A. A., Widenmaier, R., Curran, D., Espié, E., Mrkvan, T., Oostvogels, L., Simone, B., McElhaney, J. E., Burnett, H. F., Haeussler, K., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.014 · Cited by 58
Self-citation
Varicella zoster virus vaccines: an update
Gabutti, G., Bolognesi, N., Sandri, F., Florescu, C., & Stefanati, A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s176383 · Cited by 57
The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives
Costanzo, V., & Roviello, G. N. (2023) · Vaccines · doi:10.3390/vaccines11020333 · Cited by 60
Ulcerative, Vesicular, and Bullous Lesions
Woo, S. B., Setterfield, J. F., & Greenberg, M. S. (2021) · doi:10.1002/9781119597797.ch3 · Cited by 56
Age-related changes in the immune system and challenges for the development of age-specific vaccines
Doherty, M. T., Weinberger, B., Didierlaurent, A. M., & Lambert, P. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2477300 · Cited by 69
How I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 55
Managing Risks with Biologics
Click, B. H., & Regueiro, M. D. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0669-6 · Cited by 55
Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients
Lenfant, T., Jin, Y., Kirchner, E., Hajj‐Ali, R. A., Calabrese, L. H., & Calabrese, C. M. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab139 · Cited by 54
Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
Godeaux, O., Kovac, M., Shu, D., Grupping, K., Cámpora, L., Douha, M., Heineman, T. C., & Lal, H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1265715 · Cited by 53
Self-citation
Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 60
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study
Lal, H., Põder, A., Cámpora, L., Geeraerts, B., Oostvogels, L., Abeele, C. V., & Heineman, T. C. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.019 · Cited by 52
Self-citation
Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections
POOLMAN, J. T. (2020) · npj Vaccines · doi:10.1038/s41541-020-00232-0 · Cited by 53
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
Curran, D., Kim, J. H., Matthews, S., Dessart, C., Levin, M. J., Oostvogels, L., Riley, M. E., Schmader, K. E., Cunningham, A. L., McNeil, S., et al. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16917 · Cited by 51
Self-citation
New treatment strategies for ulcerative colitis
Panés, J., & Alfaro, I. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1343668 · Cited by 50
Effectiveness of herpes zoster vaccination in an older United Kingdom population
Walker, J. L., Andrews, N. J., Amirthalingam, G., Forbes, H. J., Langan, S., & Thomas, S. L. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.021 · Cited by 50
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
Oostvogels, L., Heineman, T. C., Johnson, R. W., Levin, M. J., McElhaney, J. E., den Steen, P. V., Zahaf, T., Dagnew, A. F., Chlíbek, R., Díez‐Domingo, J., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1627818 · Cited by 50
Self-citation
Modeling Varicella Zoster Virus Persistence and Reactivation – Closer to Resolving a Perplexing Persistent State
Laemmle, L. L., Goldstein, R. S., & Kinchington, P. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01634 · Cited by 50
Vaccine approaches for antigen capture by liposomes
Zhou, S., Luo, Y., & Lovell, J. F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2274479 · Cited by 52
Herpes Zoster: A Brief Definitive Review
Cohen, E. J., & Jeng, B. H. (2021) · Cornea · doi:10.1097/ico.0000000000002754 · Cited by 48
A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations
Parikh, R., Widenmaier, R., & Lecrenier, N. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1956906 · Cited by 48
Healthy ageing: Herpes zoster infection and the role of zoster vaccination
Curran, D., Doherty, T., Lecrenier, N., & Breuer, T. (2023) · npj Vaccines · doi:10.1038/s41541-023-00757-0 · Cited by 45
Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
Curran, D., Oorschot, D. V., Varghese, L., Oostvogels, L., Mrkvan, T., Colindres, R. E., von Krempelhuber, A., & Anastassopoulou, A. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1345399 · Cited by 48
Self-citation
Comparative Immune Responses to Licensed Herpes Zoster Vaccines
Weinberg, A., Kroehl, M., Johnson, M. J., Hammes, A., Reinhold, D., Lang, N., & Levin, M. J. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy383 · Cited by 48
Self-citation
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
Hastie, A., Catteau, G., Enemuo, A., Mrkvan, T., Salaun, B., Volpe, S. V., Smetana, J., Rombo, L., Schwarz, T. F., Pauksens, K., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa300 · Cited by 48
Self-citation
Varicella-zoster virus reactivation and the risk of dementia
Polisky, V., Littmann, M., Triastcyn, A., Horn, M., Georgiou, A., Widenmaier, R., Anspach, B., Tahrat, H., Kumar, S., Buser‐Doepner, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03972-5 · Cited by 50
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II
Crum‐Cianflone, N. F., & Sullivan, E. L. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0165-y · Cited by 47
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient
Kamboj, M., & Shah, M. K. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.02.007 · Cited by 50
Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
Parikh, R., Singer, D., Chmielewski-Yee, E., & Dessart, C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2263979 · Cited by 46
Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance
Guidara, C. L., Adamo, R., Sala, C., & Micoli, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105487 · Cited by 53
Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records
Klein, N. P., Bartlett, J., FIREMAN, B. H., Marks, M. A., Hansen, J. R., Lewis, E. M., Aukes, L. L., & Saddier, P. (2023) · BMJ · doi:10.1136/bmj-2023-076321 · Cited by 49
Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014)
Arruti, M., Piñeiro, L., Salicio, Y., Cilla, G., Goenaga, M., & de Munaín, A. L. (2017) · Journal of NeuroVirology · doi:10.1007/s13365-017-0519-y · Cited by 46
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
Kovac, M., Lal, H., Cunningham, A. L., Levin, M. J., Johnson, R. W., Cámpora, L., Volpi, A., & Heineman, T. C. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.029 · Cited by 45
Self-citation
Immune responses to zoster vaccines
Levin, M. J., & Weinberg, A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1560918 · Cited by 46
Self-citation
Impfen bei Immundefizienz
(2018) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2761-8 · Cited by 45
Herpes Zoster Vaccines
Cunningham, A. L., & Levin, M. J. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy382 · Cited by 44
Self-citation
Vaccines: An achievement of civilization, a human right, our health insurance for the future
Rappuoli, R., Santoni, A., & Mantovani, A. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20182160 · Cited by 44
Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)
Curran, D., Matthews, S., Rowley, S. D., Young, J. H., Bastidas, A., Anagnostopoulos, Α., Barışta, İ., Chandrasekar, P. H., Dickinson, M. J., Idrissi, M. E., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.07.036 · Cited by 44
Self-citation
Management of the Elderly Inflammatory Bowel Disease Patient
Hruz, P. L., Juillerat, P., Kullak-Ublick, G. A., Schoepfer, A. M., Mantzaris, G. J., Rogler, G., & on behalf of Swiss IBDnet, A. O. W. G. O. T. S. S. O. G. (2020) · Digestion · doi:10.1159/000503099 · Cited by 44
Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study
Díez‐Domingo, J., Curran, D., Cambronero, M. D. R., García-Martínez, J.-A., & Matthews, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01717-7 · Cited by 44
Self-citation
Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions
Sullivan, K. M., Farraye, F. A., Winthrop, K. L., Willer, D. O., Vink, P., & Silva, F. T. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.063 · Cited by 43
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans
Sullivan, N., Monslow, M. A., Sei, J. J., Dürr, E., Davis, C. W., Chang, C. Y., McCausland, M. M., Wieland, A., Krah, D. L., Rouphael, N., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00269-18 · Cited by 43
Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain
Mareque, M., Oyagüez, I., Moraño, R. B., & Casado, M. Á. (2019) · Public Health · doi:10.1016/j.puhe.2018.10.015 · Cited by 43
Management of elderly ulcerative colitis in Japan
Higashiyama, M., Sugita, A., Koganei, K., Wanatabe, K., Yokoyama, Y., Uchino, M., Nagahori, M., Naganuma, M., Bamba, S., Kato, S., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01580-y · Cited by 41
Infections in the older population: what do we know?
Schoevaerdts, D., Sibille, F., & Gavazzi, G. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01375-4 · Cited by 46
Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States
Lu, A., Sun, Y., Porco, T. C., Arnold, B. F., & Acharya, N. R. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.017 · Cited by 43
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
Marra, Y., & Lalji, F. (2022) · Viruses · doi:10.3390/v14122667 · Cited by 42
Challenges in the Vaccination of the Elderly and Strategies for Improvement
Soegiarto, G., & Purnomosari, D. (2023) · Pathophysiology · doi:10.3390/pathophysiology30020014 · Cited by 45
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
King, C., & Harper, L. (2017) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-017-0082-y · Cited by 42
Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies
Zorzoli, E., Pica, F., Masetti, G., Franco, E., Volpi, A., & Gabutti, G. (2018) · Aging Clinical and Experimental Research · doi:10.1007/s40520-018-0956-3 · Cited by 43
Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine
Silva, F. T. D., Co, M. M., Dessart, C., Hervé, C., López‐Fauqued, M., Mahaux, O., Holle, L. V., & Stegmann, J. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.11.058 · Cited by 42
CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01
Bosteels, C., Fierens, K., Prijck, S. D., Moorleghem, J. V., Vanheerswynghels, M., Wolf, C. D., Chalon, A., Collignon, C., Hammad, H., Didierlaurent, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606805 · Cited by 43
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
McGirr, A. A., Oorschot, D. V., Widenmaier, R., Stokes, M., Ganz, M. L., Jung, H., Varghese, L., & Curran, D. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00491-6 · Cited by 41
Optimizing Immunization Strategies in Patients with IBD
Caldera, F., Ley, D., Hayney, M. S., & Farraye, F. A. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa055 · Cited by 40

Authors: Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
Affiliations: The University of Sydney (AU)
Uppsala University (SE)
ORCID: Cunningham, Anthony L.
Lal, Himal
Hwang, Shinn-Jang
Godeaux, Olivier
Levin, Myron J.
McElhaney, Janet E.
Watanabe, Daisuke
Zahaf, Toufik
Athan, Eugene
de Looze, Ferdinandus
Gorfinkel, Iris
McNeil, Shelly A.
Oostvogels, Lidia
Rombo, Lars
Smetana, Jan
Weckx, Lily
Yeo, Wilfred
Heineman, Thomas C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-09-15
Volume: 375
Issue: 11
Pages: 1019-1032
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603800
OpenAlex: W2519957152
Cited by: 1,070
References: 31
Citations by year: 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
FWCI: 106.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Online (University of Wollongong) (submittedVersion)
Figshare (submittedVersion, cc-by)
CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Funders: Bristol-Myers Squibb
Pfizer
AstraZeneca
Sanofi
Novo Nordisk
Astellas Pharma
H. Lundbeck A/S
Sanofi Pasteur
Topics: Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords: herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
MeSH terms: Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks